SpectRUm – Roseman University Joins Elite Research Ranks with Carnegie Classification

In a significant milestone for the Intermountain region’s academic landscape, Roseman University of Health Sciences has been designated as a Research College and University (RCU) in the 2025 Carnegie Classifications. This prestigious recognition places Roseman among a select group of institutions acknowledged for their substantial research contributions.

The newly introduced RCU classification honors institutions that demonstrate significant research activity, exceeding $2.5 million in annual expenditures. Roseman now stands as one of only three Nevada institutions with a Carnegie research classification, alongside the University of Nevada, Las Vegas (UNLV) and the University of Nevada, Reno (UNR), both of which hold the highest-tier R1 status.

While the Carnegie Classification only lists an institution’s designation in one state, Roseman’s research excellence extends to its South Jordan, Utah, campus, particularly supporting dental medicine research. Roseman’s research in Nevada and Utah aligns with the broader bioscience growth in the Intermountain West region, where Utah has experienced the fastest growth in biopharmaceutical and medical device employment nationwide, boasting more than 1,000 life sciences companies and nearly 35,000 employees. In Utah, Roseman joins University of Utah, Brigham Young University and Utah State University as the only four institutions with Carnegie Classification for research in the state.

“This recognition validates Roseman University’s mission to advancing healthcare through innovative research and academic excellence,” said Jeffery Talbot, PhD, Vice President of Research and Dean of the College of Graduate Studies. “Our graduate-level education programs—master’s degrees in biomedical sciences and pharmaceutical sciences—along with our research initiatives, are creating new knowledge and discoveries that contribute to our region’s growing bioscience ecosystem.”

Roseman’s faculty conducts research across several critical healthcare domains, including cancer, drug discovery and development, drug formulation, and clinical research in dental medicine.

Over the past decade, Roseman has strategically invested in research infrastructure and support services, most notably through the establishment of the Bioscience Collaborative in Southern Nevada. This initiative partners with the Las Vegas Global Economic Alliance, the Nevada Governor’s Office of Economic Development, and BiotechVegas to attract bioscience companies and startups to the region.

“The Bioscience Collaborative represents our commitment not just to research excellence but also to the economic development of Southern Nevada,” Dr. Talbot explained. “By creating a hub for biotechnology and healthtech innovation, we’re offering a comprehensive physical and resource environment where scientists and educators collaborate to conduct research and create new breakthroughs.”

Dr. Talbot is also working with BioUtah to promote Roseman’s workforce development programs in the state.

Nationwide, 218 institutions received the RCU classification in 2025, while 139 institutions earned R2 classification (requiring $5 million in research spending and 20 research doctorates annually), and 187 institutions achieved the prestigious R1 designation (requiring $50 million in research spending and 70 research doctorates annually).

This achievement not only enhances Roseman University’s academic reputation but also positions it as a growing contributor to Nevada’s and Utah’s diversifying economies and advancing healthcare landscape.